Shenzhen Hepalink Pharmaceutical Group Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 2,000

Employees
  • Stock Symbol
  • 002399

Stock Symbol
  • Investments
  • 13

  • Share Price
  • $2.56

  • (As of Wednesday Closing)

Shenzhen Hepalink Pharmaceutical Group General Information

Description

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in the supply of heparin sodium drugs. The company distributes its products both in the domestic and overseas markets. Its projects portfolio includes National Bio-High Technology Industrialization Demonstration, the National Torch Program, and the National Key Technology Innovation Project. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; and CDMO business.

Contact Information

Formerly Known As
Shenzhen Hepalink Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
SHE
Primary Office
  • Number 21, Langshan Road, Songping Mountain
  • Shenzhen, Guangdong Sheng 518057
  • China
+86 0755 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shenzhen Hepalink Pharmaceutical Group Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.56 $2.56 $1.65 - $2.97 $3.4B 1.47B 6.6M $0.04

Shenzhen Hepalink Pharmaceutical Group Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 3,278,526 3,806,527 3,949,172 4,148,737
Revenue 1,090,761 985,767 771,801 669,305
EBITDA 72,539 104,038 267,044 257,996
Net Income 51,715 37,290 148,251 153,316
Total Assets 3,166,314 2,997,784 2,912,142 2,194,138
Total Debt 996,971 887,057 864,047 916,594
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shenzhen Hepalink Pharmaceutical Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shenzhen Hepalink Pharmaceutical Group‘s full profile, request access.

Request a free trial

Shenzhen Hepalink Pharmaceutical Group Patents

Shenzhen Hepalink Pharmaceutical Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210032376-A1 Glycosaminoglycan derivative and preparation method therefor and use thereof Pending 02-Feb-2018 000000000
EP-3561048-A1 Heparinase producing pseudomonas stutzeri strain and heparinase derived therefrom Pending 22-Dec-2016 00000000
EP-3561048-A4 Heparinase producing pseudomonas stutzeri strain and heparinase derived therefrom Pending 22-Dec-2016 00000000 0
JP-2020501585-A Heparinase-producing pseudomonas stutzeri strain and heparinase obtained therefrom Granted 22-Dec-2016 00000000 0
JP-6863626-B2 Heparinase-producing pseudomonas stazzeri strain and the heparinase obtained from it Active 22-Dec-2016 C12N9/88
To view Shenzhen Hepalink Pharmaceutical Group’s complete patent history, request access »

Shenzhen Hepalink Pharmaceutical Group Executive Team (4)

Name Title Board Seat Contact Info
Xianqing Xiang Chief Financial Officer & Vice President, Finance
Tan Li Board Member & General Manager
Bin Zhang Vice President, Finance & Executive Director
You’re viewing 3 of 4 executive team members. Get the full list »

Shenzhen Hepalink Pharmaceutical Group Board Members (7)

Name Representing Role Since
00000 0000 Self Board Member 000 0000
00 00 Shenzhen Hepalink Pharmaceutical Group Chairman & Board Member 000 0000
000 00 Shenzhen Hepalink Pharmaceutical Group Board Member & General Manager 000 0000
You’re viewing 3 of 7 board members. Get the full list »

Shenzhen Hepalink Pharmaceutical Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shenzhen Hepalink Pharmaceutical Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shenzhen Hepalink Pharmaceutical Group‘s full profile, request access.

Request a free trial

Shenzhen Hepalink Pharmaceutical Group Investments & Acquisitions (13)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 14-Aug-2020 0000 00.000 Pharmaceuticals
00000000000 01-Apr-2019 0000 000.00 Pharmaceuticals
00000000 0000 27-Feb-2018 00000 0000 Other Healthcare Services 00 00
00000000000 04-Dec-2017 0000 0000 Pharmaceuticals
Resverlogix 20-Jun-2017 Public Investment 2nd Offering 00.000 Pharmaceuticals
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Shenzhen Hepalink Pharmaceutical Group Subsidiaries (1)

Company Name Industry Location Founded
00000000 000 Pharmaceuticals 0000
To view Shenzhen Hepalink Pharmaceutical Group’s complete subsidiaries history, request access »

Shenzhen Hepalink Pharmaceutical Group Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 24-Nov-2016 00000 00000 00 00000 Completed
  • 6 buyers
000000 00000000000 01-Aug-2015 00000 00000 00 00.000 Completed
  • 00000000 00000000
Liminal Biosciences 08-Jan-2013 PIPE 000.00 Completed
To view Shenzhen Hepalink Pharmaceutical Group’s complete exits history, request access »